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Salyka M. Sengsayadeth,1 Shivani Srivastava,2 Madan Jagasia,1 Bipin N. Savani1Although allogeneic hematopoietic stem cell transplant (allo-HSCT) is performed to treat otherwise incur-
able and fatal diseases, transplantation itself can lead to life-threatening complications due to organ damage.
Pulmonary complications remain a significant barrier to the success of allo-HSCT. Lung injury, a frequent
complication after allo-HSCT, and noninfectious pulmonary deaths account for a significant proportion of
non-relapse mortality. Bronchiolitis obliterans syndrome (BOS) is a common and potentially devastating
complication. BOS is now considered a diagnostic criterion of chronic graft-versus-host-disease (cGVHD),
andNational Institutes of Health (NIH) consensus has been published to establish guidelines for diagnosis and
monitoring of BOS. It usually occurs within the first 2 years but may develop as late as 5 years after trans-
plantation. Recent prevalence estimates suggest that BOS is likely underdiagnosed, and when severe BOS
does occur, current treatments have been largely ineffective. Prevention and effective novel approaches re-
main the primary tools in the clinician’s arsenal in managing BOS. This article provides an overview of the
currently available and novel strategies for BOS, and we also discuss specific preventive interventions to
reduce severe BOS after allo-HSCT. Therapeutic trials continue to be needed for this orphan disease.
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Currently, more than 40,000 patients undergo
allogeneic hematopoietic stem cell transplant (allo-
HSCT) annually throughout the world, and numbers
are increasing rapidly. Long-term survival after allo-
HSCT has improved significantly since its inception
over 40 years ago due to improved supportive care
and early recognition of long-term complications [1].
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6/j.bbmt.2012.03.008of care moves beyond cure of the original disease to
the identification and treatment of chronic complica-
tions that can affect quality of life. Chronic graft-
versus-host-disease (cGVHD) has attracted the most
attention, and it is commonly linked to long-term
complications after allo-HSCT.
Lung injury is a frequent complication after trans-
plantation, and noninfectious pulmonary deaths
account for significant proportions of posttransplanta-
tion morbidity and mortality [2-5]. Delayed pulmonary
injury can also occur, and the lifetime risk of chronic
pulmonary dysfunction in long-term allo-HSCT survi-
vors ranges from 30% to 60%, depending on donor
source and elapsed time from transplantation [2,4].
Bronchiolitis obliterans syndrome (BOS) is a common
and potentially devastating noninfectious pulmonary
complication. BOS is now considered as one of the
diagnostic criteria for establishing the presence of
cGVHD by the NIH consensus report [5,6]. It is
specifically associated with insidious onset, high
morbidity and mortality, and it is characteristically
accompanied by other alloimmune symptoms of
cGVHD such as involvement of the liver, skin, or eyes.
Clinically, patients present with dyspnea on exertion,
decreased exercise tolerance, or nonproductive cough1479
1480 Biol Blood Marrow Transplant 18:1479-1487, 2012S. M. Sengsayadeth et al.with their degree of symptomatology paralleling their
degree of obstruction on pulmonary function testing
(PFT).
In the field of lung transplantation, BOS is a partic-
ularly pervasive process that is the major limiting fac-
tor that reduces overall survival (OS) and quality of
life. More than one-half of the patients who undergo
lung transplantations who survive to 5 years will de-
velop BOS [7]. Thus, many treatment modalities in
the post–allo-HSCT setting have been modeled after
data derived from the lung transplant literature. Sev-
eral treatment options remain plagued by lack of
strong evidence of efficacy, with the majority of evi-
dence based on small case series. In fact, most of the
published literature regarding BOS after allo-HSCT
involves less than 20 patients, making it difficult to
meaningfully conclude their efficacy (Table 1). Rather,
current recommendations on therapy are based largely
on consensus rather than evidence.
Pathogenesis
The lack of good therapeutic options may be re-
lated to the paucity of knowledge on the pathogenesis
of BOS. Alloimmunity is postulated to be involved,
given that BOS is also seen after lung transplant as
a form of chronic graft dysfunction, and thus BOS after
lung and allo-HSCT are thought to be similar from an
immunologic and pathologic standpoint [5]. BOS is
usually associated with concurrent involvement of
other organs such as skin, gut, liver, or eyes with
GVHD, which further lends support to the role of
alloimmunity. Moreover, development of symptoms
is usually temporally related to withdrawal of immuno-
suppression [8].
The role of immunologic cells and various cyto-
kines in the pathogenesis of both acute and cGVHD
remains controversial. As with other forms of
GVHD, involvement of donor T cells is thought to
be central in the development of BOS. Differentiation
of these donor T cells into T helper (Th) cells (eg,
Th1, Th2, and Th17 cells) may be tissue-specific,
and Th2 andTh17 cells may be specifically augmented
in lung tissue damage [9]. In the lung transplant liter-
ature, animal models have shown that the initial
alloimmune response is of the Th1 type with Inter-
feron-g (IFN-g) being the predominant cytokine.
IFN-g then up-regulates other costimulatory mole-
cules that further enhance the alloimmune response
by stimulating lymphocyte infiltration and priming T
cell responses. This further leads to a profibrotic mi-
lieu in the airways, which is thought to contribute to
development of BOS [7]. The cytokine, TNF-alpha
(TNF-a), has also been shown to be a possible predic-
tor of early onset cGVHD [10].
Because GVHD develops despite immunomodu-
lation of T cells in allo-HSCT, this suggests that other
pathways are involved in the pathogenesis of GVHD.Murine models have shown that B cells may also be in-
volved [11]. B cells are known to be involved in pro-
ducing highly specific antibodies, but their role in
other immune functions, such as antigen presentation
to T cells, immune regulation, and cytokine secretion,
are being investigated [12]. There is some evidence
that patients with cGVHD have higher levels of acti-
vated memory B cells and higher levels of B cell acti-
vating factor [13,14]. Thus, immunomodulation
through targeting of B cells and their cytokines make
sense in therapeutic strategies for BOS.
Diagnosis
Recently, a National Institutes of Health (NIH)
consensus has been published to establish guidelines
for diagnosis and monitoring of disease in patients
with cGVHD, including BOS [6]. Specifically, BOS
is characterized by a fixed airflowobstruction that is de-
fined as: (1) decreased 1-second forced expiratory vol-
ume (FEV1) \75% of predicted, and evidence of
airway obstruction as demonstrated by FEV1/forced
vital capacity ratio of\0.7 on PFT; (2) signs of air trap-
ping by PFT as shown by residual volume .120% of
predicted or evidence of air trapping on computed
tomography or lung biopsy; (3) absence of acute respi-
ratory infection; and (4) another manifestation of
cGVHD in additional organ system if no histologic
evidence of BOS can be demonstrated.
Despite improvements in the past decade of treat-
ment and survival of patients with cGVHD, such has
not been seen in patients with BOS [5]. Recent pro-
posals have beenmade tomodify the present definition
to enhance sensitivity, allowing for earlier diagnosis
and prevention of progression of BOS to more ad-
vanced stages [5,15]. Early identification strategies
are already being implemented in the lung transplant
field with use of the degree of FEV1 decline from
pretransplantation as a strategy to identify patients
earlier who may be developing BOS. Furthermore,
early onset of BOS has recently been reported to have
worse outcomes than late onset BOS, suggesting that
the early versus late onset BOS may be two distinct
clinical entities that may require different treatment
approaches [16]. Recent retrospective studies have re-
ported high mortality rates in patients diagnosed with
BOS and cGVHD regardless of therapy [15]. This
clearly indicates that treatment strategies need to be
implemented early, and novel strategies and agents
are urgently needed to improve outcomes.
Commonly Used Therapeutic Interventions
Corticosteroids
The mainstay of therapy has been use of immuno-
suppressive agents including high-dose corticoste-
roids, cyclosporine, azathioprine, and anti-thymocyte
globulin [5]. Sullivan et al. [17] first described in
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ries of 52 patients with cGVHD as effective therapy.
Since then, systemic high-dose corticosteroids are
thought to be the most efficacious treatment in
cGVHD with standard dosing usually at 1 mg/kg/day.
Ratjen et al. [18] showed improvement in FEV1 with
7 of 9 patients in the pediatric population after allo-
HSCT with clinical stability after being treated with
high-dose methylprednisolone for BOS. There is no
data in the adult population specifically evaluating
efficacy of systemic corticosteroids for BOS.
It should be noted that systemic high-dose corti-
costeroids are well known to be fraught with acute
complications such as opportunistic infections and
hyperglycemia. Furthermore, multiple late effects
after allo-HSCT, such as osteoporosis, avascular ne-
crosis, and cataracts, can cause additional morbidity
and mortality [1]. Despite this and the lack of strong
evidence, systemic corticosteroids remain the recom-
mended first-line therapy for patients diagnosed with
BOS [19].
Inhaled corticosteroids
Inhaled corticosteroids have also been evaluated
retrospectively as a modality that may optimize local
therapy while abrogating the risks of systemic corti-
costeroids in treatment of BOS. Bashoura et al. [20]
used fluticasone propionate in patients with BOS
after allo-HSCT and reported stabilization or im-
provement in FEV1 after 3 to 6 months of treatment
in 16 of 17 patients. Similarly, Bergeron et al. [21] re-
ported improvement in symptoms as well as in FEV1
at 3 to 6 months post-therapy using a combination of
budesonide and formoterol. This strategy has yet to
be evaluated in a prospective randomized controlled
manner, but the potential to deliver high doses of
steroid therapy in the inhaled modality is a promising
method of improving treatment without the systemic
risks.
Systemic immunosuppression therapy
Other immunosuppressive agents such as calci-
neurin inhibitors (cyclosporine and tacrolimus), mam-
malian target of rapamycin (mTOR) inhibitors
(sirolimus and everolimus), as well as mycophenolate
mofetil, have also been shown to be efficacious in
treatment of BOS in patients who undergo lung trans-
plant [22-25]. Strategies such as alternation and
combination of the various immunosuppressants
have been tried in the lung transplant population as
well. Unfortunately, there have been no trials
specifically targeting patients who have undergone
allo-HSCT. Rather, they have been used empirically
in patients who undergo allo-HSCT for treatment of
BOS. Despite the lack of evidence, it is commonly
used as second-line therapy after systemic corticoste-
roids for treatment of BOS [19].Azithromycin
Azithromycin, a macrolide antibiotic, has been
shown to modulate cytokine production and impair
neutrophil function. Several small studies in the lung
transplant literature have shown that chronic therapy
with azithromycin can improve FEV1 or slow progres-
sion of BOS [26-28]. The largest study reported to
date has been byVos et al. [29] whose cohort of 107 pa-
tients who underwent lung transplantation with BOS
were evaluated on long-term azithromycin therapy.
Forty percent of patients were responsive to treatment,
and these patients were reported to have improved OS
compared with those who did not respond to macro-
lide therapy. The same authors have also published
data that prophylactic azithromycin thrice weekly for
2 years after transplantation may prevent BOS by im-
proving FEV1 as well as BOS-free survival in the
same cohort [30]. Khalid et al. [31] reported significant
clinical improvement in FEV1 and forced vital capacity
in 7 of 8 patients with BOS after allo-HSCT using azi-
thromycin 500 mg daily for 3 days followed by 250 mg
thrice weekly for a minimum of 12 weeks. Given its
ease of administration and favorable side effect profile,
it is being increasingly used as upfront therapy for BOS
and is recommended as adjunctive therapy in addition
to corticosteroids and immunosuppressants [19].Novel Agents
Leukotriene receptor antagonists
Leukotriene receptor antagonists such as montelu-
kast (Singulair) have been additionally added to in-
haled corticosteroids and macrolide antibiotics to
help improve outcomes in BOS. Based on studies
that showed inflammation and eosinophilic activation
may be involved in the pathogenesis of GVHD, leuko-
triene receptor antagonists have been postulated to be
effective in posttransplantation BOS [32-34]. Or et al.
[35] described in a cohort of 5 patients with BOS that
the addition of montelukast to immunosuppressive
and chronic macrolide therapy seemed to improve pul-
monary function in some patients with cGVHD after
allo-HSCT. Verleden et al. [36] evaluated the impact
of adding montelukast therapy in patients who under-
went lung transplant with BOS and showed that the
addition significantly reduced the decline in FEV1 in
the treated group from an average of 112 mL/month
to 13 mL/month. Similarly to azithromycin, this
drug is currently being used in therapy for BOS in
the post allo-HSCT setting due to its well-tolerated
side effect profile and ease of administration. A clinical
trial is ongoing to investigate if montelukast given
once daily for 6 months improves or stabilizes lung
function as well as other forms of cGVHD in patients
with BOS after allo-HSCT (www.clinicaltrials.gov
NCT00656058).
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Norman et al. [37] have reported in a case series of
8 patients who underwent allo-HSCT with BOS that
combination therapy with fluticasone, azithromycin,
and montelukast (FAM) may attenuate the need for
prolonged systemic corticosteroid therapy. Their re-
sults indicate that prednisone exposure was 25% less
in their cohort than that of historically matched pa-
tients, suggesting that combination therapy may spare
some patients from systemic steroids. Currently, there
is a prospective phase II trial under way to determine if
the combination treatment of FAM administered in
post allo-HSCT recipients after the diagnosis of new
onset BOS can decrease the rate of treatment failure
(www.clinicaltrials.gov NCT01307462).
Extracorporeal photopheresis
Extracorporeal photopheresis (ECP) is amethod of
immunotherapy that has been used in treatment of ste-
roid refractory BOS [38,39]. It involves extracorporeal
removal of peripheral bloodmononuclear cells that are
then exposed to photoactivated 8-methoxypsoralen
and subsequently reinfused into patients. The mecha-
nism of action is not entirely clear, but is felt to involve
regulatory T cells. It has been demonstrated to be effi-
cacious in treatment of cutaneousT cell lymphoma and
autoimmune diseases such as scleroderma [40] as well
as effective therapy for cGVHD post allo-HSCT
[41,42]. Recently,Morell et al. [43] reported promising
results with ECP in a series of 8 patients with BOS in
the lung transplant population in which it has been
shown to reduce progression of disease. Similarly,
Lucid et al. [38] have shown a response rate (RR) of
67% in 9 patients who had failed systemic therapy
with corticosteroids and combination therapy with in-
haled steroids, azithromycin, and montelukast after
allo-HSCT. ECP also seemed to stabilize rapidly de-
clining PFTs in this case series of advanced refractory
BOS [38]. It is also a generally well-tolerated treatment
and is deemed to be a steroid-sparing modality of ther-
apy for cGVHD, including BOS [40]. Larger studies
are needed to evaluate the efficacy of this treatment.
Imatinib mesylate
The tyrosine kinase inhibitor, imatinib mesylate,
has been reported to be an effective agent in patients
with BOS after allo-HSCT; however, most reported
data are small case series [44,45]. It has been shown
that patients with fibrotic or sclerotic manifestations
of cGVHD (skin, lung, and bowel) have antibodies
activating the platelet-derived growth factor receptor
[46], which is involved in regulation of tissue scarring
by chronic inflammation [47]. Olivieri et al. [45] have
described the use of low-dose imatinib of 100 to 200
milligrams daily in 19 patientswithmildBOSanddem-
onstrated that the drug was active and well tolerated.RR at 6 months was seen in 79% of patients, and an
18-month OS rate of 84% was demonstrated. Addi-
tionally, some steroid-dependent patients were able
to have their steroid doses reduced or discontinued al-
together as a result of therapy with imatinib. The drug
has also been similarly reported to be effective in scle-
rodermatous GVHD [48]. However, Stadler et al.
[49] suggest that imatinib may have limited efficacy in
more advanced BOS in a series of 9 patients in which
only 2 patients showed response to therapy. This high-
lights that early and advanced BOS may be clinically
distinct entities that may require different treatment
strategies. Further confirmatory studies regarding use
of tyrosine kinase inhibitors are needed. Considering
a favorable side effects profile at low doses, it may be
an ideal drug to be considered in combinations with
other effective agents in clinical trials for BOS.
Rituximab
Accumulating evidence is emerging that suggests
B cells are involved in the pathogenesis of cGVHD
[50]. Donor B cell alloantibody deposition and germi-
nal center formation are reported to be required for the
development of murine cGVHD and BOS [11]. Ritux-
imab, which is an anti-CD20 chimeric monoclonal an-
tibody that targets B cells, is used for treatment of
a variety of B cell malignancies. It has also been used
to treat autoimmune diseases, the pathogenesis of
which is very similar to cGVHD. Several small studies
have shown that rituximab is effective in treatment of
steroid refractory cGVHD [51-54]. A phase I/II
study by Cutler et al. [53] demonstrated in their cohort
of 21 patients with cutaneous and musculoskeletal
manifestations of cGVHD,RRs of 70%with rituximab
therapy, with 2 patients having complete responses.
Responses were durable up to 1 year post-therapy
and also permitted more rapid tapering of chronic sys-
temic corticosteroids (median reduction of dose from
40 mg/day to 10 mg/day). However, not all data sup-
ports efficacy of rituximab. A recent case series of 3 pa-
tients showed that rituximab was not effective therapy
for severe advanced BOS in post allo-HSCT recipients
[55]. Again, this indicates that treatment strategies may
need to be tailored to the severity of the BOS.
Aerosolized therapy
One of the newer approaches to BOS has been the
use of aerosolized therapy to facilitate direct administra-
tion of immunosuppressive drugs to the lungs, enhanc-
ing therapeutic effect along with minimizing systemic
toxicities. Iacano et al. [56] reported improvement in
OS as well as chronic rejection-free survival in lung
transplant patients that received inhaled cyclosporine
at a dose up to 300 mg for 10 consecutive days and
then 3 times weekly for 2 years. Their survival analysis
showed that those receiving placebo had a 5-fold higher
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sporine. Subsequent analysis of pulmonary function pa-
rameters in the same cohort of patients indicated
improved lung function parameters (change in FEV1,
FEV25-75, and percent decline of FEV1) [57]. Inhaled
cyclosporine provides several fold higher local concen-
tration than systemic administration without added sys-
temic toxicity. More recently, a case report of inhaled
tacrolimus showed subjective improvement in dyspnea
and clinical improvement as measured by the 6-minute
walk test [58]. There is currently no published long-
term data on use of inhaled cyclosporine in the allo-
HSCTpopulation. There is currently an ongoing phase
II clinical trial evaluating the safety, efficacy, and phar-
macodynamics of inhaled cyclosporine for treatment
ofBOS in both the allo-HSCTand lung transplant pop-
ulations (www.clinicaltrials.gov NCT01287078). A
phase III, multicenter, randomized controlled clinical
trial to evaluate the efficacy and safety of inhaled cyclo-
sporine when added to standard immunosuppressive
regimens has been completed with results pending
(www.clinicaltrials.gov NCT00755781).
TNF-a inhibitors
Because TNF-a has been shown to be a possible
predictor of early onset of cGVHD [10,12], use of
TNF-a inhibitors have been evaluated in BOS. Several
case series using TNF-a inhibitors, such as infliximab
and etanercept, have been reported as therapy for
BOS, although they remain experimental, especially in
light of their potential infectious complications
[59-61]. A current phase II trial that has completed
enrollment is evaluating the role of etanercept in
treating subacute lung injury in the post allo-HSCTset-
ting (www.clinicaltrials.gov NCT00141726).
Bortezomib
Bortezomib, a first generation proteasome inhibi-
tor, has been shown to induce apoptosis in activated
allo-reactive T cells via caspase activation. It has also
been shown to decrease activation of Th1 cells
in vivo [62]. It is known to inhibit the cytokine, trans-
forming growth factor-beta 1, which plays a role in tis-
sue repair and fibrosis. It has also been shown to be
effective in reversal of allo-antibody mediated rejec-
tion in patients who undergo renal transplant [63]
and is currently being studied in patients who undergo
lung transplant with encouraging results [64]. This
drug has also shown promising results in a Phase I trial
as prophylaxis of GVHD [65]. Bortezomib is currently
being tested in patients greater than 100 days after
allo-HSCT in a Phase II open-label clinical trial in
BOS (www.clinicaltrials.gov NCT01163786).
Lung transplant
Consideration of lung transplant upon failure of
medical therapy is also an option with several casesreported in the literature on post-allogeneic transplan-
tation [66-68]. As stem cell transplant offers curative
therapy, lung transplant is a viable option for
patients who are thought to have achieved a cure for
their hematologic malignancy but have severe BOS.
Currently, there are no defined criteria for the
appropriate timing for referral to a lung transplant,
but those who have remained in remission for years
without significant comorbidities or other long-term
complications from allo-HSCT may be good candi-
dates for consideration.Time to Explore Preventive Strategies for BOS
after HSCT
Current management is not completely effective,
and progressive BOS is associated with high morbidity
andmortality after allo-HSCT.Novel but easily appli-
cable preventive strategies are needed to prevent or de-
crease the severity of BOS to serve the needs of the
increasingly enlarging population of high-risk allo-
HSCT recipients.
Anti-infective therapy is a standard practice used
post allo-HSCT to prevent bacterial infections. Peni-
cillin, fluoroquinolones, and azithromycin are com-
monly used agents. Azithromycin, an effective agent
against capsulated organisms, needs to be tested in
the posttransplantation setting with the dual goal of
preventing infection and possibly BOS. Given its
ease of administration and favorable side effect profile
with long-term use in lung transplant recipients, it is
time to test this strategy in preventive trials in patients
after allo-HSCT.
Rituximabhas been evaluated as preemptive therapy
in patients with Epstein-Barr virus re-activation after
allo-HSCT. However, use of rituximab posttransplan-
tation risks delaying recovery of a donor-derived B cell
immune response. Rituximab therapy 2 months after
allo-HSCT prevents donor B cell reconstitution up to
1 year after transplantation [69,70]. The half-life of rit-
uximab,despite the influenceof the tumorburden, could
range from several days to months. However, if rituxi-
mab is used during the conditioning regimen, this theo-
retically might have less impact on donor-derived B cell
reconstitution compared to posttransplantation admin-
istration for BOS where effects are long lasting. The
optimal dose of rituximab during the conditioning reg-
imen to inducemaximumbenefit and prevent long-term
side effects remains to be determined, but a single low
dose during conditioning seems attractive. A study has
shown that low-dose subcutaneous rituximab effectively
depletes low burdens ofCD20positive B cells [71], a sit-
uation comparable to most allo-HSCT recipients
(excluding some with B cell malignancies) at the time
of conditioning. Moreover, peritransplantation use of
rituximab may result in greater protection from BOS
by additionally depleting donor B cells [51,72,73].
Table 1. Available Therapeutic Options for BOS after allo-HSCT
Agent Mechanism of Action Author No. of Patients Results Current Clinical Trials
Systemic corticosteroids Systemic immunosuppression Ratjen et al. [18] 9 (children) Improvement in FEV1 at 2 months. None
Inhaled corticosteroids Localized anti-inflammatory Bergeron et al. [21] 13 >10% improvement in FEV1 in all of 13 patients
with combined after 3-6 months of treatment
budesonide and formoterol.
Phase II trial: efficacy of budesonide/formoterol
(clinicaltrials.gov NCT00624754).
Bashoura et al. [20] 17 Stabilization or improvement of FEV1 in 16 of 17
patients after 3-6 months of treatment with
fluticasone proprionate.
Calcineurin inhibitors Systemic immunosuppression None None
Mycophenolate mofetil Inhibits fibroblast proliferation None None
mTOR inhibitors Inhibits fibroblast proliferation None None
Azithromycin Macrolide antibiotic impairs neutrophilic
inflammation? Prokinetic GI properties
leading to reducing of GERD.
Khalid et al. [31] 8 >12% improvement in FEV1 in 7 of 8 patients. None
Montelukast Leukotriene receptor antagonist reduces
bronchoconstriction, eosinophilic, and
neutrophilic recruitment.
Or et al. [35] 5 >30% improvement in FEV1 in 3 of 5 patients. Phase II trial: once-daily montelukast for 6
months after allogeneic or autologous stem
cell transplantation in children and adults
(clinicaltrials.gov NCT00656058).
Extracorporeal
photopheresis
Mechanism not understood. Involvement
of regulatory T cells.
Lucid et al. [38] 9 67% response rate in patients who previously
failed steroids.
Two studies evaluating all patients with
cGVHD and efficacy with ECP are
completed (clinicaltrials.gov
NCT00248365 NCT00048789).
Couriel et al. [42] 11 5 of 11 with partial response; 1 patient with
complete response.
Imatinib Anti-fibrinogenic Oliveri et al. [45] 6 4 of 6 able to have IST tapered or discontinued. None
Rituximab Inhibits B cell proliferation (anti-CD20
antibody)
Lorillion et al. [55] 3 0 of 3 patients with response. None
Inhaled cyclosporine Local immunosuppressant therapy None Phase II trial: efficacy of inhaled cyclosporine
in both patients who underwent lung
transplant and allo-HSCT (clinicaltrials.gov
NCT01287078).
Etanercept TNF-a blockade None Phase II trial: response to etanercept
(clinicaltrials.gov NCT00141726).
Bortezomib Proteosome inhibitor
Inhibits TGF-b1
None Phase II trial: improvement in FEV1 with
bortezomib (clinicaltrials.gov
NCT01163786).
Combination therapy Norman et al. [37] 8 25% less systemic corticosteroid exposure. Pilot study: improvement in FEV1 at 6 months
with azithromycin, N-acetylcysteine and
inhaled corticosteroid combination
(clinicaltrials.gov NCT01327625).
Phase II trial: efficacy of FAM (clinicaltrials.gov
NCT01307462).
BOS indicates bronchiolitis obliterans syndrome; HSCT, hematopoietic stem cell transplantation; FEV1, forced expiratory volume in 1 second; mTOR, mammalian target of rapamycin; GI, gastrointestinal; GERD,
gastroesophageal reflux disease; cGVHD, chronic graft-versus-host disease; ECP, extracorporeal photopheresis; IST, immunosuppressive therapy; TGF-b1, transforming growth factor beta-1; FAM, fluticasone, azi-
thromycin, and montelukast.
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Biol Blood Marrow Transplant 18:1479-1487, 2012 1485BOS after HSCTSirolimus (rapamycin), aside from its inhibitory
effects on normal cells of the immune system, also
inhibits proliferation of transformed cell lines.
Experimental studies suggest that sirolimus inhibits
growth of transformed B-lymphocytes. Sirolimus has
been shown to be effective in GVHD prophylaxis after
allo-HSCT [74]; however, the prevalence of BOS after
sirolimus use has not been reported. Another benefit is
that mTOR inhibitors are effective against a number
of malignancies, and they may also add antitumor
activity that could be helpful in eliminating residual
disease post-HSCT in certain settings [75].
Combining anti-infective prophylaxis with azith-
romycin, low-dose rituximab, and sirolimus GVHD
prophylaxis (with other immunosuppressive agents)
may significantly reduce the expense, morbidity, and
mortality associated with BOS in high-risk popula-
tions. All of these approaches need to be evaluated in
clinical trials.CONCLUSION
BOS, an often fatal manifestation of cGVHD, re-
mains a diagnostic and therapeutic challenge in the
post allo-HSCT setting. Although consensus on initial
therapies exists, there is still a significant lack of strong
evidence regarding the efficacy and safety of these
treatment modalities in BOS. Further trials are
urgently needed to prevent morbidity and mortality
associated with BOS. Better identification of pretrans-
plantation factors associated with BOS is also needed
to define patients at greatest risk who might benefit
from preventive strategies.ACKNOWLEDGMENT
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